Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: liraglutide

First Posted Date: 2014-10-02

Last Posted Date: 2018-04-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1788

Registration Number: NCT02255266

Locations: 🇮🇹
Novo Nordisk Investigational Site, Rome, Italy

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: sitagliptin

First Posted Date: 2014-10-01

Last Posted Date: 2018-09-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 308

Registration Number: NCT02254291

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan

Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: semaglutide
Drug: metformin
Drug: digoxin
Drug: placebo

First Posted Date: 2014-09-26

Last Posted Date: 2020-02-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT02249910

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: semaglutide
Drug: Omeprazole

First Posted Date: 2014-09-26

Last Posted Date: 2018-08-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 54

Registration Number: NCT02249871

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: semaglutide
Drug: digoxin
Drug: atorvastatin

First Posted Date: 2014-09-17

Last Posted Date: 2017-04-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 31

Registration Number: NCT02243098

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B
Haemophilia B With Inhibitors
Relatives to/Carers of Patients
Haemophilia A With Inhibitors
Haemophilia A

Interventions: Other: No treatment given

First Posted Date: 2014-09-16

Last Posted Date: 2015-07-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 200

Registration Number: NCT02241694

Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass

Phase 1

Completed

Conditions: Acquired Bleeding Disorder
Cardiac Surgery Requiring Cardiopulmonary Bypass

Interventions: Drug: placebo
Drug: catridecacog

First Posted Date: 2014-09-12

Last Posted Date: 2017-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 43

Registration Number: NCT02239146

Locations: 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: NNC9204-0530
Drug: placebo
Drug: liraglutide

First Posted Date: 2014-09-10

Last Posted Date: 2017-07-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 163

Registration Number: NCT02235961

Locations: 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States

Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: semaglutide

First Posted Date: 2014-09-04

Last Posted Date: 2015-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 42

Registration Number: NCT02231684

A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2014-09-03

Last Posted Date: 2015-04-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 704

Registration Number: NCT02230631

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy